Objective: To evaluate safety, tolerability, and antitumor activity of pembrolizumab monotherapy in patients with programmed death ligand 1 (PD-L1)-expressing advanced ovarian cancer enrolled in the multicohort, phase Ib KEYNOTE-028 trial VSports手机版. .

Methods: Key inclusion criteria were age ≥18 years; advanced ovarian epithelial, fallopian tube, or primary peritoneal carcinoma; failure of previous therapy; and tumor PD-L1 positivity. Patients received pembrolizumab (10 mg/kg every 2 weeks) for ≤24 months or until disease progression/intolerable toxicity. Tumor response was assessed per RECIST v1. 1 (investigator review). Adverse events (AEs) were graded using CTCAE version 4. 0. Primary end point was confirmed objective response rate (ORR) per RECIST v1. 1 (investigator review); data cutoff date was February 20, 2017. V体育安卓版.

Results: Twenty-six patients (median age, 57. 5 years) with PD-L1-positive advanced metastatic ovarian cancer received pembrolizumab; 38. 5% had metastatic disease, and 73. 1% previously received ≥3 lines of therapy. Treatment-related AEs (TRAEs) occurred in 19 (73. 1%) patients, most commonly arthralgia (19. 2%), nausea (15 V体育ios版. 4%), and pruritus (15. 4%). One grade 3 TRAE (increased plasma transaminase level) occurred. No deaths and no treatment discontinuations due to TRAEs occurred. After a median follow-up duration of 15. 4 months, ORR was 11. 5% (1 complete response, 2 partial responses); 7 patients (26. 9%) achieved stable disease. Median progression-free and overall survival were 1. 9 (95% CI, 1. 8-3. 5) and 13. 8 (95% CI, 6. 7-18. 8) months, respectively. .

Conclusion: Pembrolizumab conferred durable antitumor activity with manageable safety and toxicity in patients with advanced PD-L1-positive ovarian cancer and is under further investigation in an ongoing phase II trial, KEYNOTE-100. VSports最新版本.